Literature DB >> 31142693

Intrahepatic Cholestasis of Pregnancy as a Clinical Manifestation of Sodium-Taurocholate Cotransporting Polypeptide Deficiency.

Rong Chen1, Mei Deng1, Yaqub-Muhammad Rauf1, Gui-Zhi Lin1, Jian-Wu Qiu1, Shun-Ye Zhu2, Xiao-Min Xiao3, Yuan-Zong Song1.   

Abstract

Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-related liver disorder. Although the etiology of ICP is not fully understood thus far, some genetic factors might contribute to the development of this condition. Sodium-taurocholate cotransporting polypeptide (NTCP), the protein encoded by the gene Solute Carrier Family 10, Member 1 (SLC10A1), is the primary transporter expressed in the basolateral membrane of the hepatocyte to uptake conjugated bile salts from the plasma. NTCP deficiency arises from biallelic SLC10A1 mutations which impair the NTCP function and cause intractably elevated levels of total bile acids (TBA) in the plasma (hypercholanemia). In this study, all the SLC10A1 exons and their flanking sequences were analyzed by Sanger sequencing to investigate the etiology for hypercholanemia in two male infants aged 2 and 20 months, respectively, from two unrelated families. As a result, both patients are homozygous for the reported pathogenic variant c.800C>T (p.Ser267Phe) that could impair the NTCP function to uptake bile acids, and the diagnosis of NTCP deficiency was thus made. Their mothers are also homozygotes of the same variant and both had been diagnosed to have ICP in the third trimester, with one of them undergoing cesarean section. The father of the first patient in this paper has the same SLC10A1 genotype c.800C>T/c.800C>T, also exhibiting slight hypercholanemia with a plasma TBA level of 21.5 μmol/L. In conclusion, we suggest that with hypercholanemia being a common laboratory change, NTCP deficiency may be a genetic factor leading to ICP and even cesarean section in clinical practice.

Entities:  

Keywords:  SLC10A1; bile acid; hypercholanemia; intrahepatic cholestasis of pregnancy; sodium taurocholate cotransporting polypeptide deficiency

Mesh:

Substances:

Year:  2019        PMID: 31142693     DOI: 10.1620/tjem.248.57

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  4 in total

1.  Molecular Epidemiology of Na+-Taurocholate Cotransporting Polypeptide Deficiency in Guangdong Province, China: A Pilot Study by Screening for Four Prevalent Variants of the Causative Gene SLC10A1.

Authors:  Hua Li; Rong Chen; Gui-Zhi Lin; Wei-Xia Lin; Muhammad-Rauf Yaqub; Yuan-Zong Song
Journal:  Front Genet       Date:  2022-04-27       Impact factor: 4.599

2.  De novo mutation loci and clinical analysis in a child with sodium taurocholate cotransport polypeptide deficiency: A case report.

Authors:  Hui-Yan Liu; Meng Li; Qi Li
Journal:  World J Clin Cases       Date:  2021-12-26       Impact factor: 1.337

3.  Clinical and molecular characterization of four patients with NTCP deficiency from two unrelated families harboring the novel SLC10A1 variant c.595A>C (p.Ser199Arg).

Authors:  Hua Li; Mei Deng; Li Guo; Jian-Wu Qiu; Gui-Zhi Lin; Xiao-Ling Long; Xiao-Min Xiao; Yuan-Zong Song
Journal:  Mol Med Rep       Date:  2019-10-23       Impact factor: 2.952

4.  Clinical characterization of NTCP deficiency in paediatric patients : A case-control study based on SLC10A1 genotyping analysis.

Authors:  Li-Jing Deng; Wen-Xian Ouyang; Rui Liu; Mei Deng; Jian-Wu Qiu; Muhammad-Rauf Yaqub; Muhammad-Atif Raza; Wei-Xia Lin; Li Guo; Hua Li; Feng-Ping Chen; Ying Ouyang; Yu-Ge Huang; Yue-Jun Huang; Xiao-Ling Long; Xiao-Ling Huang; Shuang-Jie Li; Yuan-Zong Song
Journal:  Liver Int       Date:  2021-08-25       Impact factor: 8.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.